Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Inhibidores de la fosfodiesterasa"'
Publikováno v:
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J [Internet]. 2015;46(4):903–75.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl):D42–D50.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;24;53(1):1.
Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
López Reyes R, Nauffal Manzur D, Garcia Ortega A, Menéndez Salinas MA, Ansotegui Barrera E, Balerdi Perez B. Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. Clin Respir J. 2017];11(1):103–12.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142(2):448–56.
Scherrer U, Allemann Y, Rexhaj E, Rimoldi SF, Sartori C. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol. 2013;14(2):126–33.
Gali N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–6.
Kemp K, Savale L, O’Callaghan DS, Jaís X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Hear Lung Transplant. 2012;31(2):150–8.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin V V., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med [Internet]. 2015; 373(9):834–44.
Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314–22.
Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev. 2012;21(126):321–7.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM, Hemodynamic thresholds for pre-capillary pulmonary hypertension, CHEST (2015), doi: 10.1378/chest.15-0928.
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018.
Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carrier in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033.
Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000 Sep;2(3):273-80.
Baba, M., Yoshida, K., & Ieda, M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. International Journal of Molecular Sciences. 2019; 20 (11), 2824. doi:10.3390/ijms20112824.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Curr Cardiovasc Risk Rep. 2021;15(1):2. doi: 10.1007/s12170-020-00663-3. Epub 2020 Nov 18.
Simonneau, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American journal of respiratory and critical care medicine. 2002; 165(6), 800–804.
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Badagliacca, R., Pezzuto, B., Poscia, R., Mancone, M., Papa, S., Marcon, S., … Vizza, C. D. (2012). Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation, 31(4), 364–372. doi:10.1016/j.healun.2011.12.011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(Suppl):D42–D50.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;24;53(1):1.
Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med. 2017;141(5):696.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–22.
López Reyes R, Nauffal Manzur D, Garcia Ortega A, Menéndez Salinas MA, Ansotegui Barrera E, Balerdi Perez B. Clinical characteristics and survival of patients with pulmonary hypertension: a 40-month mean follow-up. Clin Respir J. 2017];11(1):103–12.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012; 142(2):448–56.
Scherrer U, Allemann Y, Rexhaj E, Rimoldi SF, Sartori C. Mechanisms and drug therapy of pulmonary hypertension at high altitude. High Alt Med Biol. 2013;14(2):126–33.
Gali N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31(17):2080–6.
Kemp K, Savale L, O’Callaghan DS, Jaís X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Hear Lung Transplant. 2012;31(2):150–8.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin V V., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med [Internet]. 2015; 373(9):834–44.
Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314–22.
Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev. 2012;21(126):321–7.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–36.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl):D51–D59.
Gerges C, Gerges M, Skoro-Sajer N, Zhou Y, Zhang L, Sadushi-Kolici R, Jakowitsch J, Lang MB, Lang IM, Hemodynamic thresholds for pre-capillary pulmonary hypertension, CHEST (2015), doi: 10.1378/chest.15-0928.
Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.01904-2018.
Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic characterization of EIF2AK4 mutation carrier in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 2017; 136: 2022–2033.
Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000 Sep;2(3):273-80.
Baba, M., Yoshida, K., & Ieda, M. Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. International Journal of Molecular Sciences. 2019; 20 (11), 2824. doi:10.3390/ijms20112824.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.
Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Curr Cardiovasc Risk Rep. 2021;15(1):2. doi: 10.1007/s12170-020-00663-3. Epub 2020 Nov 18.
Simonneau, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American journal of respiratory and critical care medicine. 2002; 165(6), 800–804.
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Badagliacca, R., Pezzuto, B., Poscia, R., Mancone, M., Papa, S., Marcon, S., … Vizza, C. D. (2012). Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation, 31(4), 364–372. doi:10.1016/j.healun.2011.12.011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: El tratamiento de la hipertensión pulmonar arterial es un reto clínico, ya que requiere una estrategia compleja y multidisciplinaria, fundamentada en el uso de vasodilatadores pulmonares. Las investigaciones actuales se enfocan princ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85cbf8a483b7b09d730b237df5a21cbf
https://repository.urosario.edu.co/handle/10336/32223
https://repository.urosario.edu.co/handle/10336/32223
Autor:
Andreu Casas, Marta
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Antecedentes El manejo de los pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) muy severa fenotipo bronquítico crónico en fase estable de la enfermedad supone un reto terapéutico. La triple terapia formada por corticoides inhalados ju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::026ea8f248a1c805a83895c51f465c46
http://hdl.handle.net/20.500.12328/1679
http://hdl.handle.net/20.500.12328/1679
Publikováno v:
Revista Mexicana de Urología. 76(6):360-369
Recent interest in the coadministration of approved pharmaceutical agents has resulted in a wealth of emerging data on the safety and efficacy of dual pharmacological treatment for lower urinary tract symptoms (LUTS). Much evidence supports the coadm
Autor:
Miguel García Sanz
Publikováno v:
GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname
instname
La disfuncion erectil (DE) consiste en una incapacidad de conseguir y/o mantener una ereccion suficiente para la actividad sexual. Presenta una gran prevalencia en la poblacion y esta asociada a factores como la edad, alteraciones de etiologia primar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a71895b9b411f25b15546ad2c9f018c5
https://hdl.handle.net/10366/140413
https://hdl.handle.net/10366/140413
Autor:
Juan A. Mazzei, Jorge O. Cneva, Sergio V. Perrone, Marcelo J. Melero, Juan J. Scali, Guillermo Bortman
Publikováno v:
Medicina (Buenos Aires), Vol 71, Iss suppl 1, Pp 1-48 (2011)
El trmino hipertensin pulmonar agrupa a un conjunto heterogneo de enfermedades que tienen en comn una remodelacin obstructiva del lecho vascular pulmonar. Esta alteracin provoca un estado hemodinmico caracterizado por una elevacin sostenida de la pre
Autor:
Mora Cuesta, Víctor Manuel, Martínez Meñaca, Amaya, Cifrián Martínez, José Manuel, Iturbe Fernández, David, Fernández Rozas, Sonia, Zurbano Goñi, Felipe
Publikováno v:
REV MED VALDECILLA. 2015:0(1).
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
RESUMEN: La Hipertensión Pulmonar (HP) se define por un aumento en la presión arterial pulmonar media ≥ 25 mmHg en reposo calculada por el cateterismo cardiaco derecho, y la hipertensión arterial pulmonar (HAP) como un grupo de enfermedades cró
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::bdf7a03152e20745da1e827947e4d355
http://hdl.handle.net/10902/13789
http://hdl.handle.net/10902/13789
Autor:
A. Cassinello Hervás, I. Moncada Iribarren, B. Sanz Terrada, J. Casariego García-Lubén, M. Chan, N. Cruz Navarro, A. Martín-Morales
Publikováno v:
Actas Urológicas Españolas v.30 n.8 2006
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Fundamento y objetivo: Comparar eficacia y seguridad de tadalafilo 20 mg administrado 3 veces/semana ("pautado") vs. "a demanda" en una cohorte de españoles con disfunción eréctil (DE) aprovechando que su efecto permanece hasta 36 horas post-dosis
Autor:
Martín-Morales, A., Moncada Iribarren, I., Cruz Navarro, N., Sanz Terrada, B., Cassinello Hervás, A., Chan, M., Casariego García-Lubén, J.
Publikováno v:
Actas Urológicas Españolas, Volume: 30, Issue: 8, Pages: 791-800, Published: SEP 2006
Fundamento y objetivo: Comparar eficacia y seguridad de tadalafilo 20 mg administrado 3 veces/semana ("pautado") vs. "a demanda" en una cohorte de españoles con disfunción eréctil (DE) aprovechando que su efecto permanece hasta 36 horas post-dosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______624::bf190846a2c70455cf9a94fac668341b
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0210-48062006000800007&lng=en&tlng=en
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0210-48062006000800007&lng=en&tlng=en
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Balmori C; IVI Madrid, Universidad Rey Juan Carlos, Madrid, España. Electronic address: carlos.balmori@ivi.es., Badiola C; Departamento Médico, Casen Recordati S.L., Madrid, España.
Publikováno v:
Revista internacional de andrologia [Rev Int Androl] 2018 Apr - Jun; Vol. 16 (2), pp. 67-74. Date of Electronic Publication: 2018 Mar 14.